Succesful results in developing oral vaccine against diarrhea

May 22, 2013
Succesful results in developing oral vaccin against diarrhea. Credit: The University of Gothenburg

The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.

Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of diarrhea in children living in low and result in 400 million diarrheal episodes and approximately 300 000 deaths among children per year.

ETEC is also the leading cause of illness among to developing countries. Among the 65 million people travelling from industrialized countries to ETEC high-risk areas in the developing world, 30-50 % (ca 30 million people) experience at least one TD episode during their journey. Today there is no ETEC vaccine available on the market for use in either children or travelers in ETEC high-risk areas.

A novel oral ETEC vaccine has been developed in Sweden and a clinical phase I-study of this vaccine has now been successfully completed. All predefined primary endpoints for the study were achieved showing that the vaccine is safe, with only few and mild adverse reactions observed, and strongly immunogenic, stimulating immune responses to all vaccine components.

The vaccine, consisting of four inactivated E. coli and the ETEC-based B subunit protein LCTBA, was studied for safety and in a total of 129 healthy volunteers. The study was designed as a four-armed, double-blinded, placebo-controlled trial. were randomized to receive two two weeks apart of either the vaccine alone, vaccine co-administered with an oral adjuvant in a low or a higher dose, or an inactive placebo preparation (a buffer solution).

In addition to safety parameters, against various vaccine components in , or antibodies produced by intestine-derived peripheral blood lymphocytes were measured at different time intervals.

The vaccine was well tolerated by the study participants. Adverse events were few and generally mild with no difference observed in subjects receiving vaccine or a placebo preparation. In total, 75% of all vaccine recipients responded to all 5 of the primary vaccine components, a result that well exceeds the primary immunological endpoint for the study (at least 50 percent of the subjects responding to at least 4 of the primary vaccine antigens).

Furthermore, 85 % of subjects receiving the vaccine co-administered with low dose adjuvant showed significant immune responses to all vaccine components. In addition to showing excellent safety and immunogenicity of the five-component vaccine, the results also confirm previous preclinical results as well as clinical results obtained with a prototype version of this vaccine.

This study was conducted at the Sahlgrenska Academy of University of Gothenburg as a collaborative effort between University of Gothenburg Institute, Scandinavian Biopharma, Stockholm and the non-profit organization PATH, Washington D.C. The results will be presented at the Mucosal Vaccines, Adjuvants and Delivery Conference in Copenhagen, September 25-27 2013 and the 7th International Conference on Vaccines for Enteric Diseases, 6-8 November 2013 in Bangkok, Thailand.

Based on these very encouraging results, additional clinical studies are planned to document protective efficacy in travelers, and to study the safety and immunogenicity of the vaccine when given to children living in areas endemic for ETEC.

Explore further: Competing antibodies may have limited the protection achieved in HIV vaccine trial in Thailand

Related Stories

Competing antibodies may have limited the protection achieved in HIV vaccine trial in Thailand

May 6, 2013
Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.

Lyme disease vaccine shows promise in clinical trial

May 13, 2013
(Medical Xpress)—The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at Baxter International ...

New discovery may lead the way to improved whooping cough vaccine

May 13, 2013
Scientists at Trinity College Dublin have made novel discoveries concerning the current vaccine against whooping cough that may lead to the development of an improved future vaccine. The findings could help reduce the incidence ...

India announces low-cost rotavirus vaccine (Update)

May 14, 2013
The Indian government announced Tuesday the development of a new low-cost vaccine proven effective against a diarrhea-causing virus that is one of the leading causes of childhood deaths across the developing world.

Study finds why some don't respond to rubella vaccine

May 1, 2013
Using advanced genetic sequencing technology and analysis, Mayo Clinic vaccine researchers have identified 27 genes that respond in very different ways to the standard rubella vaccine, making the vaccine less effective for ...

Whole-cell vaccine was more effective than acellular vaccine during CA pertussis outbreak

May 20, 2013
Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.